#United States #San Francisco, CA #Biotech Showcase #Diakonos Oncology #DOC1021

Diakonos Oncology to Present at Biotech Showcase 2025

Diakonos Oncology, a pioneering clinical-stage biotechnology company based in Houston, Texas, is gearing up to showcase its latest advancements in cancer treatment at the prestigious Biotech Showcase 2025. This event, which takes place in San Francisco, California from January 13-15, 2025, presents a prime opportunity for innovative companies like Diakonos to connect with global investors and industry leaders.

Key Highlights of the Presentation

During the showcase, President and COO Jay Hartenbach will take the stage to discuss significant milestones and the latest research developments from Diakonos. Central to the presentation will be the company's lead product, DOC1021, an autologous dendritic cell vaccine (DCV) designed to tackle late-stage and aggressive cancers, particularly glioblastoma (GBM).

Upcoming Phase 2 Clinical Trial

The presentation is set for January 15, 2025, at 11:15 AM PST in the Yosemite C Ballroom at the Hilton San Francisco – Union Square. Hartenbach is particularly eager to share encouraging clinical data that has surpassed expectations regarding patient survival and the ongoing recruitment of participants for the Phase 2 clinical trial of DOC1021, which is slated to begin in the first half of 2025 at top oncology centers across the United States.

Innovative Approach of DOC1021

What sets DOC1021 apart is its unique formulation, which invokes a robust cytotoxic T helper 1 (TH1) immune response against tumors by leveraging the company’s proprietary double loading technology. This innovative technique integrates both protein and RNA antigen sources, offering a comprehensive attack on the tumor antigen profile. Notably, this method boasts an excellent safety record without the need for myelosuppressive preconditioning chemotherapy or reducing doses of interleukin-2 (IL-2).

Hartenbach emphasized, "Our cellular vaccine uniquely targets the tumor’s complete antigen profile, fostering powerful memory T cell responses against some of the most aggressive cancers. We are thrilled to present the clinical trial outcomes that demonstrate our product’s efficacy and safety."

Expansion of Clinical Trials

In addition to the GBM study, DOC1021 is also undergoing evaluation in a Phase 1 clinical trial focused on pancreatic ductal adenocarcinoma (PDAC), with an aim to complete enrollment by the end of this year. Encouragingly, Diakonos has received Fast Track designations from the FDA for both its GBM and PDAC programs, alongside Orphan Drug Designation for the GBM initiative.

The Future of Diakonos Oncology

Diakonos Oncology is dedicated to revolutionizing cancer immunotherapy and addressing unmet therapeutic needs in challenging-to-treat cancers. As the company continues to advance its clinical programs, it remains focused on pushing the boundaries of cancer treatment, particularly through groundbreaking products like DOC1021. With plans for a refractory melanoma study on the horizon, Diakonos is poised to make significant strides in the field.

For those interested in learning more about the Biotech Showcase or scheduling one-on-one meetings during the event, further information is available on the Biotech Showcase website.

To learn more about Diakonos Oncology and their innovative research, visit Diakonos Oncology.